Should we abandon a 50-plus-year history of panretinal photocoagulation (PRP)? In this article we discuss the significant research that has been done to answer these questions and provide …

Feb 21, 2022 · Studies such as Protocol S demonstrated that anti-VEGF alone is noninferior to PRP, whereas some studies, such as CLARITY, demonstrated superior visual outcome …

To evaluate the efficacy and safety of anti-VEGF and panretinal photocoagulation (PRP) for the treatment of proliferative diabetic retinopathy (PDR). The outcomes examined are changes in …

Oct 1, 2024 · In this retrospective cohort study, findings suggest that patients with PDR treated with PRP first then subsequent anti-VEGF injection are more likely to undergo PPV for VH and …

Treatment with PRP and subsequent anti-VEGF injection was associated with higher rates of VH at 5 years (RR, 1.40; 95% CI, 1.09-1.80; RD, 6.47%; 95% CI, 1.66%-11.29%; P < .001) and …

Anti-vascular endothelial growth factor (VEGF) medications are an emerging treatment alternative and supplement to PRP. Anti-VEGF treatments are associated with much decreased …

May 1, 2019 · Panretinal photocoagulation (PRP) remains the gold standard of initial therapy for proliferative diabetic retinopathy (PDR) and its neovascular complications despite a recent …

Jun 11, 2024 · PRP has fallen out of favor in recent years as anti-VEGF is more sparing of the retina and generally safer, with comparable results. This study showed differences in …

We demonstrated that VEGF attenuation in PRP did not inhibit the effect of PRP on chondrogenic differentiation of stem cells in vitro. In addition, healing of rat OA cartilage was significantly …

Purpose: To evaluate the long-term effects of ranibizumab compared with panretinal photocoagulation (PRP) on retinal vasculature in eyes with proliferative diabetic retinopathy …